Channeling effects in the prescription of new therapies: the case of emicizumab for hemophilia A-论文-万方医学网

Channeling effects in the prescription of new therapies: the case of emicizumab for hemophilia A

导出原文传递

翻译打印收藏纠错

作者： Mahajerin, Arash ^[1] ; Faghmous, Imi ^[2] ; Kuebler, Peter ^[3] ; Howard, Monet ^[4] ; Xu, Tao ^[5] ; Flores, Carlos ^[6] ; Chang, Tiffany ; Nissen, Francis

作者单位： Div Pediat Hematol,Univ Calif Irvine ^[1] Dept Real World Data Oncol Hematol,F Hoffmann La Roche Ltd ^[2] Dept Personalized Healthcare Safety Interface,Genentech Inc ^[3] Dept Clin Safety,F Hoffmann La Roche Ltd ^[4] Dept Personalized Healthcare Prod Dev,F Hoffmann La Roche Ltd ^[5] Dept Evidence Strategy,Genesis Res ^[6]

关键词 channeling claims data coagulation factor VIII comorbidity emicizumab healthcare systems hemophilia A pharmacovigilance safety PROPHYLAXIS REPLACEMENT INHIBITORS SAFETY

发布时间 2022-12-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除